JX09 vs Vicadrostat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertension

Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline

JX09

Developed by Ji Xing Pharmaceuticals (CORXEL)

Phase 1 in Hypertensionsmall molecule
Partial signal

NCT06183671 · Phase 1 · completed

This is a randomized, blinded, placebo-controlled phase 1 study in 92 healthy volunteers testing single and multiple ascending doses of JX09, with safety and tolerability as the primary focus rather than a disease efficacy measure. Results have not been posted.

No aligned efficacy figure on record for this race.

Vicadrostat

Developed by Boehringer Ingelheim

Phase 3 in Hypertensionsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2029 · NCT07064473 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointJX09Vicadrostat
Seated SBP, change—Not reported—Trial running · NCT07064473
24-hour ambulatory SBP, change—Not reported—Trial running · NCT07064473
Seated DBP, change—Not reported—Trial running · NCT07064473

Seated SBP, change

JX09
—Not reported
Vicadrostat
—Trial running · NCT07064473

24-hour ambulatory SBP, change

JX09
—Not reported
Vicadrostat
—Trial running · NCT07064473

Seated DBP, change

JX09
—Not reported
Vicadrostat
—Trial running · NCT07064473
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JX09: no structured comparison results are available for Hypertension.

Vicadrostat: no structured comparison results are available for Hypertension.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JX09's landscape · Vicadrostat's landscape